Hyo Keun Lim

Sungkyunkwan University, Seoul, Seoul, South Korea

Are you Hyo Keun Lim?

Claim your profile

Publications (98)166.39 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to compare the targeting and ablation performance between a newly developed radiofrequency (RF) electrode embedded with an electromagnetic position sensor (EMPS) at the electrode tip and a conventional RF electrode.
    Investigative radiology. 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radiofrequency ablation (RFA) has gained a wide acceptance as a first-line therapeutic option for small hepatocellular carcinoma (HCC). For very early-stage HCC, despite a higher rate of local tumor progression, RFA is considered as a viable alternative to surgical resection owing to its comparable long-term survival, reduced morbidity, and greater preservation of hepatic parenchyma. For HCCs larger than 2cm, RFA can contribute to near-curative therapy when combined with chemoembolization. RFA can be used as part of a multimodal treatment strategy for more advanced or recurrent cases, and could be a useful bridging therapy for patients who are waiting for liver transplantation. However, the use of RFA is still limited in treating large tumors and some tumors in high-risk locations. To overcome its current limitations, other ablation techniques are being developed and it is important to validate the role of other techniques for enhancing performance of ablation therapy for HCC.
    Baillière&#x027 s Best Practice and Research in Clinical Gastroenterology 10/2014; · 3.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose To determine whether semiquantitative perfusion magnetic resonance (MR) imaging parameters are associated with therapeutic effectiveness of MR imaging-guided high-intensity focused ultrasound (HIFU) ablation of uterine fibroids and which semiquantitative perfusion parameters are significant with regard to treatment efficiency. Materials and Methods This study was approved by the institutional review board, and informed consent was obtained from all subjects. Seventy-seven women (mean age, 43.3 years) with 119 fibroids (mean diameter, 7.5 cm) treated with MR imaging-guided HIFU ablation were analyzed. The correlation between semiquantitative perfusion MR parameters (peak enhancement, relative peak enhancement, time to peak, wash-in rate, washout rate) and heating and ablation efficiencies (lethal thermal dose volume based on MR thermometry and nonperfused volume based on immediate contrast-enhanced image divided by intended treatment volume) were evaluated by using a linear mixed model on a per-fibroid basis. The specific value of the significant parameter that had a substantial effect on treatment efficiency was determined. Results The mean peak enhancement, relative peak enhancement, time to peak, wash-in rate, and washout rate of the fibroids were 1293.1 ± 472.8 (range, 570.2-2477.8), 171.4% ± 57.2 (range, 0.6%-370.2%), 137.2 seconds ± 119.8 (range, 20.0-300.0 seconds), 79.5 per second ± 48.2 (range, 12.5-236.7 per second), and 11.4 per second ± 10.1 (range, 0-39.3 per second), respectively. Relative peak enhancement was found to be independently significant for both heating and ablation efficiencies (B = -0.002, P < .001 and B = -0.003, P = .050, respectively). The washout rate was significantly associated with ablation efficiency (B = -0.018, P = .043). Both efficiencies showed the most abrupt transitions at 220% of relative peak enhancement. Conclusion Relative peak enhancement at semiquantitative perfusion MR imaging was significantly associated with treatment efficiency of MR imaging-guided HIFU ablation of uterine fibroids, and a value of 220% or less is suggested as a screening guideline for more efficient treatment. © RSNA, 2014 Online supplemental material is available for this article.
    Radiology 07/2014; · 6.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE. The purposes of this study were to assess the widths of the intercostal spaces of the right inferior human rib cage through which high-intensity focused ultrasound therapy would be applied for treating liver cancer and to elucidate the demographic factors associated with intercostal space width. SUBJECTS AND METHODS. From March 2013 to June 2013, the widths of the intercostal spaces and the ribs at six areas of the right inferior rib cage (area 1, lowest intercostal space on anterior axillary line and the adjacent upper rib; area 2, second-lowest intercostal space on anterior axillary line and the adjacent upper rib; areas 3 and 4, lowest and second-lowest spaces on midaxillary line; areas 5 and 6, lowest and second-lowest spaces on posterior axillary line) were sonographically measured in 466 patients (214 men, 252 women; mean age, 53.0 years) after an abdominal sonographic examination. Demographic factors and the presence or absence of chronic liver disease were evaluated by multivariate analysis to investigate which factors influence intercostal width. RESULTS. The width of the intercostal space was 19.7 ± 3.7 mm (range, 9-33 mm) at area 1, 18.3 ± 3.4 mm (range, 9-33 mm) at area 2, 17.4 ± 4.0 mm (range, 7-33 mm) at area 3, 15.4 ± 3.5 mm (range, 5-26 mm) at area 4, 17.2 ± 3.7 mm (range, 7-28 mm) at area 5, and 14.5 ± 3.6 mm (range, 4-26 mm) at area 6. The corresponding widths of the ribs were 15.2 ± 2.3 mm (range, 8-22 mm), 14.5 ± 2.3 mm (range, 9-22 mm), 13.2 ± 2.0 mm (range, 9-20), 14.3 ± 2.2 mm (range, 9-20 mm), 15.0 ± 2.2 mm (range, 10-22 mm), and 15.1 ± 2.3 mm (range, 8-21 mm). Only female sex was significantly associated with the narrower intercostal width at areas 1, 2, 3, and 5 (regression coefficient, 1.124-1.885; p = 0.01-0.04). CONCLUSION. There was substantial variation in the widths of the intercostal spaces of the right inferior rib cage such that the anterior and inferior aspects of the intercostal space were relatively wider. Women had significantly narrower intercostal spaces than men.
    AJR. American journal of roentgenology. 07/2014; 203(1):201-8.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the value of fusion imaging with contrast-enhanced ultrasonography (CEUS) and computed tomography (CT)/magnetic resonance (MR) images for percutaneous radiofrequency ablation (RFA) of very-early-stage hepatocellular carcinomas (HCCs) that are inconspicuous on fusion imaging with B-mode ultrasound (US) and CT/MR images. This retrospective study was approved by our institutional review board and the requirement for informed consent was waived. Fusion imaging with CEUS using Sonazoid contrast agent and CT/MR imaging was performed on HCCs (<2 cm) that were inconspicuous on fusion imaging with B-mode US. We evaluated the number of cases that became conspicuous on fusion imaging with CEUS. Percutaneous RFA was performed under the guidance of fusion imaging with CEUS. Technical success and major complication rates were assessed. In total, 30 patients with 30 HCCs (mean, 1.2 cm; range, 0.6-1.7 cm) were included, among which 25 (83.3%) became conspicuous on fusion imaging with CEUS at the time of the planning US and/or RFA procedure. Of those 25 HCCs, RFA was considered feasible for 23 (92.0%), which were thus treated. The technical success and major complication rates were 91.3% (21/23) and 4.3% (1/23), respectively. Fusion imaging with CEUS and CT/MR imaging is highly effective for percutaneous RFA of very-early-stage HCCs inconspicuous on fusion imaging with B-mode US and CT/MR imaging.
    Clinical and molecular hepatology. 03/2014; 20(1):61-70.
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE. MRI-guided high-intensity focused ultrasound (HIFU) ablation is increasingly adopted for treating symptomatic uterine fibroids. As a noninvasive therapy performed on an outpatient basis, it has been viewed by patients to have distinct advantages over other treatment options. However, its breadth of clinical application is still limited. To address this issue, various techniques have been implemented. CONCLUSION. In this article, we discuss techniques that contribute to widening patient selection for MRI-guided HIFU therapy of uterine fibroids.
    American Journal of Roentgenology 02/2014; 202(2):443-51. · 2.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the enhancement of the efficacy of systemic doxorubicin by pulsed high-intensity focused ultrasound (HIFU)-induced, localized mild hyperthermia. For the in vitro study, the intranuclear uptake of doxorubicin by squamous cell carcinoma (SCC)-7 cells incubated at different temperatures was compared. For the in vivo study, mice with SCC-7 tumors were assigned to either the control, conventional hyperthermia, HIFU hyperthermia, doxorubicin-alone, conventional hyperthermia + doxorubicin or HIFU hyperthermia + doxorubicin group. Conventional hyperthermia was induced by immersing the tumor in warm water (42.5°C), and HIFU hyperthermia was induced by HIFU after optimizing the parameters with direct temperature measurements (frequency = 1 MHz, pulse repetition frequency = 5 Hz, power = 12 W, duty cycle = 50%). In the in vitro study, fluorescence was more intense at 42°C than at 37°C and was time dependent. In the in vivo study, tumor growth in the HIFU hyperthermia + doxorubicin group was most prominently suppressed with the highest apoptotic index compared with all other groups (p < 0.05). Pulsed HIFU-induced localized mild hyperthermia enhanced the anti-cancer efficacy of systemic doxorubicin more than conventional mild hyperthermia.
    Ultrasound in medicine & biology 01/2014; · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To perform a systematic review of compliance with standardized terminology and reporting criteria for radiofrequency (RF) tumor ablation, proposed by the International Working Group on Image-Guided Tumor Ablation in 2003, in the published reports. Literature search in the PubMed database was performed using index keywords, PubMed limit system, and eligibility criteria. The entire content of each article was reviewed to assess the terminology used for procedure terms, imaging findings, therapeutic efficacy, follow-up, and complications. Accuracy of the terminology and the use of alternative terms instead of standard terminology were analyzed. In addition, disparities in accuracy of terminology in articles according to the medical specialty and the type of radiology journal were evaluated. Among the articles (n = 308) included in this study, the accuracy of the terms 'procedure or session', 'treatment', 'index tumor', 'ablation zone', 'technical success', 'primary technique effectiveness rate', 'secondary technique effectiveness rate', 'local tumor progression', 'major complication', and 'minor complication' was 97% (298/307), 97% (291/300), 8% (25/307), 65% (103/159), 55% (52/94), 33% (42/129), 94% (17/18), 45% (88/195), 99% (79/80), and 100% (77/77), respectively. The overall accuracy of each term showed a tendency to improve over the years. The most commonly used alternative terms for 'technical success' and 'local tumor progression' were 'complete ablation' and 'local (tumor) recurrence', respectively. The accuracy of terminology in articles published in radiology journals was significantly greater than that of terminology in articles published in non-radiology journals, especially in Radiology and The Journal of Vascular and Interventional Radiology. The proposal for standardization of terminology and reporting criteria for RF tumor ablation has been gaining support according to the recently published scientific reports, especially in the field of radiology. However, more work is still needed for the complete standardization of terminology.
    Korean journal of radiology: official journal of the Korean Radiological Society 01/2014; 15(1):95-107. · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background. Radiofrequency ablation (RFA) as a curative therapy for hepatocellular carcinoma (HCC) is widely used. The aim of this study was to investigate predisposing factors for HCC recurrence in patients with hepatitis B virus (HBV)-related small HCC after RFA. Methods. A total of 170 patients underwent percutaneous RFA for HBV-related small HCC (≤3 cm in diameter) from January 2008 to December 2010 at Samsung Medical Center. We analyzed the risk factors for recurrence of HCC after RFA. Results. The median follow-up duration was 27.0 months. A total of 89 patients (52%) experienced recurrence after percutaneous RFA. Cumulative recurrence-free rates after RFA at 1-, 3-, and 5 years were 81.3%, 47.2% and 35.7%, respectively. Univariate analysis showed that predisposing factors for HCC recurrence were the multinodularity (hazard ratio (HR) 2.22, p = 0.005), pre-RFA HBV DNA levels ≥2000 IU/mL (HR 1.61, p = 0.025), and Barcelona Clinic Liver Cancer stage A (HR 1.54, p = 0.046). The independent risk factors for recurrence by multivariate analysis were the multinodularity (HR 1.94, p = 0.026) and pre-RFA HBV DNA levels ≥2000 IU/mL (HR 1.57, p = 0.039). Conclusion. Multinodularity and HBV DNA levels were associated with the recurrence of HBV-related small HCC after RFA.
    Scandinavian Journal of Gastroenterology 12/2013; · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the safety and therapeutic efficacy of magnetic resonance (MR) imaging-guided high-intensity focused ultrasound (US) ablation of symptomatic uterine fibroid tumors with an immediate nonperfused volume (NPV) ratio of 80% or more. A total of 79 women with 117 uterine tumors were treated with MR-guided high-intensity focused US ablation. Immediate NPV, complications, and therapeutic efficacy (tumor volume reduction ratio and symptom severity score [SSS] decrease at 3-mo follow-up) were retrospectively assessed. Statistical comparisons of the frequency of complications and therapeutic efficacy were performed between patients with NPV ratios of at least 80% and less than 80%. Technical success was achieved in 93.7% of cases (n = 74) of cases, and the immediate NPV ratio was 62.7% ± 25.5. Twenty-four patients exhibited an NPV ratio of at least 80% (89.7% ± 5.8), and 50 patients showed an NPV ratio of less than 80% (49.8% ± 20.7). All complications were minor in severity, and the incidences were not significantly different between groups (P > .05). The 3-month volume reduction ratio was significantly greater in patients with an NPV ratio of at least 80% (0.43 ± 0.17) than in those with an NPV ratio of less than 80% (0.20 ± 0.26; P = .002), although the decreases in SSS were not significantly different (20.9 ± 19.6 vs 12.1 ± 10.1; P = .097). In MR-guided high-intensity focused US ablation of symptomatic uterine fibroid tumors, achievement of an immediate NPV ratio of at least 80% is safe, with greater tumor volume shrinkage compared with cases with a lower NPV ratio.
    Journal of vascular and interventional radiology: JVIR 12/2013; · 1.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE/AIM The aim of the this exhibit is 1. To describe the imaging features and managements of various complications associated with radiofrequency ablation (RFA) 2. To review the risk factors potentially affecting RFA-induced complications 3. To determine the impact of RFA-induced complications on the long term outcomes of RFA. CONTENT ORGANIZATION Although RFA is considered to be a safe and effective technique for treating liver tumors, various complications can happen when inadequately performed. We have performed more than 6,000 RFA procedures for treating liver tumors during the recent 14 years period and encountered diverse procedure-related complications. We divided RFA-induced complications into five types: hemorrhage, hepatic vascular injuries, biliary injuries, extrahepatic organ injuries and tumor progression. SUMMARY The major teaching points of this exhibit are 1. Because an early and accurate diagnosis of complications is mandatory for proper management, radiologists should be familiar with the imaging features, as well as management strategies of RFA-induced complication. 2. Through understanding of risk factors for developing RFA-induced complications may be beneficial in preventing potential complications. 3. Physicians who perform RFA should be aware of the impact of RFA-induced complications on the long term therapeutic outcomes of RFA.
    Radiological Society of North America 2013 Scientific Assembly and Annual Meeting; 12/2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE To investigate whether it is feasible to estimate the change of hepatic venous pressure gradient (HVPG) using Supersonic shear wave elastography (SWE) in the patients with portal hypertension. METHOD AND MATERIALS Twenty-three consecutive patients who were diagnosed with portal hypertension (>=6 mmHg of HVPG) on initial HVPG measurement and who underwent follow-up measurement to evaluate response to treatment were enrolled in this retrospective study. Liver stiffness measurement was performed in all of the subjects, followed by HVPG measurement through transjugular catheterization on the same day. Liver stiffness was obtained intercostally, which was repeated 5 times at the same location of the right liver. The relationship between the HVPG and liver stiffness on initial measurement and on follow-up was investigated by using Pearson’s correlation test. Furthermore, we evaluated whether a change in the HVPG (ΔHVPG) was correlated with a change in the liver stiffness (ΔLS). The subjects were subdivided into two groups: those in whom the HVPG at follow-up decreased by >=20% compared to the initial measurement (clinical improvement), and those in whom the percentage of decrease was less than 20%. The performance to determine improvement of portal hypertension was investigated using the receiver operating characteristics (ROC) curve analysis. RESULTS Liver stiffness was significantly correlated with HVPG at initial and follow-up measurements (r=0.501 and 0.527, respectively). The mean rate and difference of ΔLS were strongly correlated with ΔHVPG (r=0.863 and 0.707, respectively). To determine the improvement of portal hypertension, the area under the ROC curve was 0.79 of rate of ΔLS, and 0.78 of difference of ΔLS. CONCLUSION Supersonic SWE is feasible method to determine improvement of portal hypertension in cirrhotic patients. CLINICAL RELEVANCE/APPLICATION Supersonic SWE is available for evaluation of improvement of portal hypertension,;therefore ;can replace;conventional invasive;catheterization.Supersonic SWE is available for evaluation of improvement
    Radiological Society of North America 2013 Scientific Assembly and Annual Meeting; 12/2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocyte specific contrast agents including gadoxetic acid and gadobenate dimeglumine are very useful to diagnose various benign and malignant focal hepatic lesions and even helpful to estimate hepatic functional reservoir. The far delayed phase image referred to as the hepatobiliary phase makes the sensitivity of detection for malignant focal hepatic lesions increased, but specificity of malignant diseases, including hepatocellular carcinoma, metastasis and cholangiocarcinoma, characterization remained to be undetermined.
    Clinical and molecular hepatology. 12/2013; 19(4):360-366.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose To compare the long-term therapeutic outcomes of radiofrequency (RF) ablation for small perivascular hepatocellular carcinoma (HCC) and nonperivascular HCC. Materials and Methods This retrospective study was approved by the institutional review board. Between December 2004 and April 2008, 241 patients (175 men and 66 women; age range, 32-82 years) with a single early-stage HCC that was 3 cm or smaller in the greatest dimension underwent ultrasonography-guided percutaneous RF ablation as a first-line treatment. The patients were divided into two groups according to the presence or absence of contacting hepatic vessels that were 3 mm or larger in axial diameter: a group with perivascular HCC (n = 58) and a group with nonperivascular HCC (n = 183). Cumulative local tumor progression, disease-free and long-term survival rates, and prognostic factors were assessed by using Cox proportional hazard models with Bonferroni correction. Results The overall median follow-up period was 58 months (range, 13-92 months). The cumulative local tumor progression rates were 10%, 16%, and 26% at 1, 3, and 5 years, respectively, in the perivascular group, and 6.7%, 15.5%, and 20.5% in the nonperivascular group; the differences were not significant (P = .323). The corresponding disease-free survival rates were 79%, 41%, and 29% in the perivascular group and 71.3%, 38.7%, and 26.0% in the nonperivascular group, with no significant difference (P = .689). The corresponding overall survival rates were 100%, 94%, and 82% in the perivascular group and 100%, 88.4%, and 73.9% in the nonperivascular group, also without significant difference (P = .267). There was no significant prognostic factor for local tumor progression, whereas extrahepatic and intrahepatic distant recurrences were significant prognostic factors for overall survival in multivariable analysis. Conclusion The long-term therapeutic outcomes of RF ablation as first-line treatment for small perivascular HCC were similar to those for nonperivascular HCC. © RSNA, 2013.
    Radiology 11/2013; · 6.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE. In MRI-guided high-intensity focused ultrasound ablation of uterine fibroids, bowel interposition in the sonication path is often problematic. The purpose of this article is to discuss a bowel-manipulation technique to displace the bowel loop, which consisted of sequential applications of urinary bladder filling, rectal filling, and urinary bladder emptying. CONCLUSION. This technique contributed to a decreased screening failure rate and succeeded in consistently displacing the bowel loop, thus allowing safe treatment of fibroids in the anteverted or anteflexed uterus.
    American Journal of Roentgenology 11/2013; 201(5):W761-4. · 2.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose:To determine whether intraprocedural thermal parameters as measured with magnetic resonance (MR) thermometry can be used to predict immediate or delayed therapeutic response after MR-guided high-intensity focused ultrasound (HIFU) ablation of uterine fibroids.Materials and Methods:Institutional review board approval and subject informed consent were obtained. A total of 105 symptomatic uterine fibroids (mean diameter, 8.0 cm; mean volume, 251.8 mL) in 71 women (mean age, 43.3 years; age range, 25-52 years) who underwent volumetric MR HIFU ablation were analyzed. Correlations between tumor-averaged intraprocedural thermal parameters (peak temperature, thermal dose efficiency [estimated volume of 240 equivalent minutes at 43°C divided by volume of treatment cells], and temperature decay rate after sonication) and the immediate ablation efficiency (ratio of nonperfused volume [NPV] at immediate follow-up to treatment cell volume) or ablation sustainability (ratio of NPV at 3-month follow-up to NPV at immediate follow-up) were assessed with linear regression analysis.Results:A total of 2818 therapeutic sonications were analyzed. At immediate follow-up with MR imaging (n = 105), mean NPV-to-fibroid volume ratio and ablation efficiency were 0.68 ± 0.26 (standard deviation) and 1.35 ± 0.75, respectively. A greater thermal dose efficiency (B = 1.894, P < .001) and slower temperature decay rate (B = -1.589, P = .044) were independently significant factors that indicated better immediate ablation efficiency. At 3-month follow-up (n = 81), NPV had decreased to 43.1% ± 21.0 of the original volume, and only slower temperature decay rate was significantly associated with better ablation sustainability (B = -0.826, P = .041).Conclusion:The postsonication temperature decay rate enables prediction of both immediate and delayed therapeutic responses, whereas thermal dose efficiency enables prediction of immediate therapeutic response to MR HIFU ablation of uterine fibroids.© RSNA, 2013.
    Radiology 09/2013; · 6.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether pretreatment evaluation with contrast-enhanced ultrasonography (CEUS) is effective for percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) with poor conspicuity on conventional ultrasonography (US). This retrospective study was approved by the institutional review board and informed consent was waived. From June 2008 to July 2011, 82 patients having HCCs (1.2 ± 0.4 cm) with poor conspicuity on planning US for RFA were evaluated with CEUS prior to percutaneous RFA. We analyzed our database, radiologic reports, and US images in order to determine whether the location of HCC candidates on planning US coincide with that on CEUS. To avoid incomplete ablation, percutaneous RFA was performed only when HCC nodules were identified on CEUS. The rate of technical success was assessed. The cumulative rate of local tumor progression was estimated with the use of the Kaplan-Meier method (mean follow-up: 24.0 ± 13.0 months). Among 82 patients, 73 (89%) HCCs were identified on CEUS, whereas 9 (11%) were not. Of 73 identifiable HCCs on CEUS, the location of HCC on planning US corresponded with that on CEUS in 64 (87.7%), whereas the location did not correspond in 9 (12.3%) HCCs. Technical success was achieved for all 73 identifiable HCCs on CEUS in a single (n = 72) or two (n = 1) RFA sessions. Cumulative rates of local tumor progression were estimated as 1.9% and 15.4% at 1 and 3 years, respectively. Pretreatment evaluation with CEUS is effective for percutaneous RFA of HCCs with poor conspicuity on conventional US.
    Korean journal of radiology: official journal of the Korean Radiological Society 09/2013; 14(5):754-63. · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). However, clinical parameters that may predict the treatment outcomes in sorafenib-treated advanced HCC patients remains unknown. METHODS: A total of 99 advanced (BCLC C) HCC patients treated with sorafenib as an initial treatment modality from January 2007 to December 2011 were retrospectively reviewed. Overall survival was the primary endpoint for the analysis. Various clinical parameters including tumour stage and adverse effects to sorafenib were analysed. Univariate and multivariate analysis were carried out to identify clinical parameters predictive of the effect of sorafenib. RESULTS: There were 86 males and 13 females included in this study, with a median age of 53 years. The median overall survival was 91 days. Sixty-nine patients had Child-Pugh class A cirrhosis and 30 patients had Child-Pugh class B cirrhosis. Hepatitis B virus was the predominant cause of HCC (75.8%). Noted adverse effects were hand-foot syndrome, diarrhoea, fatigue, abdominal pain, nausea and stomatitis. The presence of hand-foot syndrome and diarrhoea and the absence of portal vein thrombosis and lymph node metastasis predicted a better overall survival in the multivariate analysis. Excluding the absence of lymph node metastasis, the same parameters were associated with a longer radiological time to progression. CONCLUSION: Advanced HCC patients treated with sorafenib who experienced hand-foot syndrome and diarrhoea showed better overall survival than patients without these side effects. These side effects may be used as clinical parameters predictive of sorafenib response in patients with HCC.
    Liver international: official journal of the International Association for the Study of the Liver 04/2013; · 3.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To evaluate the risk factors affecting early diffuse recurrence within 1 year of percutaneous ultrasound-guided radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). METHODS: Out of 146 patients who received transcatheter arterial chemoembolisation (TACE) for treatment of recurrent HCC after percutaneous ultrasound-guided RFA, we selected 23 patients with early diffuse recurrence. Early diffuse recurrence was defined as three or more new recurrent HCCs within 1 year of initial RFA. As a control group, we selected 23 patients, matched exactly for age and sex, in which there was no local tumour progression or new recurrence after RFA. To analyse the risk factors, we examined patient factors and tumour factors. RESULTS: Recurrent tumours occurred from 30 to 365 days after RFA (median time, 203 days). Univariate analysis indicated that larger tumour size and poorly defined margin were significant risk factors (P < 0.05). Multivariate analysis indicated that poorly defined margin was a significant risk factor (P < 0.05). CONCLUSION: Larger tumour size and poorly defined margin may be risk factors for early diffuse recurrence of HCC within 1 year of RFA. Tumours with such risk factors should be treated with a combination of TACE to minimise the potential for therapeutic failure. KEY POINTS: • Ultrasound-guided radiofrequency ablation (RFA) is widely used for hepatocellular carcinoma (HCC). • Early diffuse recurrence after RFA is an important prognostic factor • The risk factors for recurrence are larger tumour size and poorly defined margins • Tumours with such risk factors should be treated with transarterial chemoembolisation.
    European Radiology 10/2012; · 4.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: To assess the treatment speed of volumetric magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) ablation of symptomatic uterine fibroids, with a focus on factors affecting treatment speed. METHODS: We received Institutional Review Board approval, and informed consent was obtained from all participants. Among 109 patients referred, 43 women (39.4 %) (mean age, 43.7 years), with 112 fibroids passed the screening. We treated 53 symptomatic uterine fibroids (47.3 %, 53/112) (volume, 341.2 ± 256.5 ml) using volumetric MR-HIFU ablation. We assessed procedure times, non-perfused volume (NPV) and treatment speed (NPV/treatment time). We statistically analysed the factors affecting treatment speed using multiple logistic regression tests. RESULTS: Technical success was achieved in 42 of 43 cases. MR room time (from entrance to exit) and treatment time (from first to last sonication) were 216.0 ± 40.6 min and 131.5 ± 55.9 min, respectively. Immediate NPV was 178.9 ± 147.3 ml, which was 57.4 ± 25.5 % of the fibroid volume. Treatment speed was 81.8 ± 48.0 ml/h. Multivariate analysis showed that a large fibroid volume (P < 0.001), a low signal intensity ratio of fibroid to skeletal muscle on T2-weighted images (P = 0.009) and timing after completion of the learning curve (P < 0.001) significantly increased treatment speed. CONCLUSION: Volumetric MR-HIFU ablation can effectively treat symptomatic uterine fibroids. The treatment speed appeared to improve when treating large and/or dark fibroids as well as upon completion of the learning curve. KEY POINTS : • High-intensity focused ultrasound (HIFU) offers another interventional radiological option for treating fibroids • Volumetric MR-guided HIFU ablation can treat uterine fibroids in a timely fashion • Treatment speed appeared to improve when treating large and/or dark fibroids • Treatment speed appeared to improve upon completion of the learning curve.
    European Radiology 10/2012; · 4.34 Impact Factor

Publication Stats

774 Citations
166.39 Total Impact Points

Institutions

  • 2005–2013
    • Sungkyunkwan University
      • • School of Medicine
      • • Samsung Medical Center
      • • Department of Radiology
      Seoul, Seoul, South Korea
  • 2012
    • University of Seoul
      Sŏul, Seoul, South Korea
  • 2006
    • Seoul Veterans Hospital
      Sŏul, Seoul, South Korea